Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment.

Literature DB >> 16055611

BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment.

Abstract

Guidelines have been compiled by The Joint Tuberculosis Committee of the British Thoracic Society to quantify the risks of reactivation of tuberculosis with anti-tumour necrosis factor alpha (anti-TNF-alpha) treatment. These guidelines are intended to inform respiratory physicians, gastroenterologists, rheumatologists and dermatologists, together with specialist nurses in those disciplines.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2005 PMID： 16055611 PMCID： PMC1747200 DOI： 10.1136/thx.2005.046797

Source DB: PubMed Journal: Thorax ISSN： 0040-6376 Impact factor: 9.139

15 in total

Review 1. Cytokine pathways and joint inflammation in rheumatoid arthritis.

Authors: E H Choy; G S Panayi
Journal: N Engl J Med Date: 2001-03-22 Impact factor: 91.245

Review 2. The treatment of tuberculosis in HIV-infected persons.

Authors: A L Pozniak; R Miller; L P Ormerod
Journal: AIDS Date: 1999-03-11 Impact factor: 4.177

3. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy.

Authors: William S Mow; Maria T Abreu-Martin; Konstantinos A Papadakis; Howard E Pitchon; Stephan R Targan; Eric A Vasiliauskas
Journal: Clin Gastroenterol Hepatol Date: 2004-04 Impact factor: 11.382

4. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics.

Authors: A M Lee; J Z Mennone; R C Jones; W S Paul
Journal: Int J Tuberc Lung Dis Date: 2002-11 Impact factor: 2.373

5. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

Authors: J Keane; S Gershon; R P Wise; E Mirabile-Levens; J Kasznica; W D Schwieterman; J N Siegel; M M Braun
Journal: N Engl J Med Date: 2001-10-11 Impact factor: 91.245

6. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.

Authors: Robert M Jasmer; Jussi J Saukkonen; Henry M Blumberg; Charles L Daley; John Bernardo; Eric Vittinghoff; Mark D King; L Masae Kawamura; Philip C Hopewell
Journal: Ann Intern Med Date: 2002-10-15 Impact factor: 25.391

10. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.

Authors: Muhammad K Nisar; Aneesa Rafiq; Andrew J K Östör
Journal: Clin Rheumatol Date: 2015-10-24 Impact factor: 2.980

BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment.

Review 1. Cytokine pathways and joint inflammation in rheumatoid arthritis.

Review 2. The treatment of tuberculosis in HIV-infected persons.

3. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy.

4. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics.

5. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

6. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.

Review 7. New drugs for the treatment of rheumatoid arthritis.

Review 8. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.

9. Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis.

10. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy.

1. Crohn's disease or TB--the perennial question and diagnostic pitfalls.

2. TNF-alpha antagonist therapy modify the tuberculin skin test response.

Review 3. [Infectious complications of biologic therapy in patients with rheumatoid arthritis].

4. A practical approach to screening psoriasis patients for therapy with biologic agents.

5. TB screening and anti-TNFalpha treatment.

6. Attenuated response to purified protein derivative in patients with rheumatoid arthritis.

Review 7. Key issues in the diagnosis and management of tuberculosis.

8. Tuberculosis and anti-TNF treatment: experience of a central London hospital.

9. Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy.

10. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.